Study summary
Adding atezolizumab to chemotherapy shrank more than half of advanced thymic carcinomas
56%had their tumors shrink
What was tested
Atezolizumab, an immunotherapy, with carboplatin and paclitaxel as first treatment for advanced or recurrent thymic carcinoma, in Japan. No comparison group.
What they found
- Tumors shrank in 56% of people.
- Low white blood cell counts were the most common serious side effect.
- There were no treatment-related deaths.
What it means
Promising, but needs a comparison against chemotherapy alone. Thymic carcinoma carries a higher risk of immune side effects than other cancers.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.